The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Open accessAbstract
Export Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)–positive ABMR. Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morphology (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were identified on cross-sectional screening of 741 patients, were randomly assigned to receive bortezomib (n=21) or placebo (n=23). The 0.5-ml/min per 1.73 m2 per year (95% confidence interval, −4.8 to 5.8) difference detected between bortezomib and placebo in eGFR slope (primary end point) was not significant (P=0.86). We detected no significant differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m2; P=0.31), 2-year graft survival (81% versus 96%; P=0.12), urinary protein concentration, DSA levels, or morphologic or molecular rejection phenotypes in 24-month follow-up biopsy specimens. Bortezomib, however, associated with gastrointestinal and hematologic toxicity. In conclusion, our trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity. Our results reinforce the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590
Self-citationHaas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Rule, A. D., Larson, T. S., Bergstralh, E. J., Slezak, J. M., Jacobsen, S. J., & Cosio, F. G. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-12-200412210-00009 · Cited by 1,066
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14107 · Cited by 629
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cited by
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Antibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
Metadata
- Authors
- Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., Oberbauer, R., Posch, M., Staudenherz, A., Handisurya, A., Reeve, J., Halloran, P. F., & Böhmig, G. A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-12-14
- Volume
- 29
- Issue
- 2
- Pages
- 591-605
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2773812249
- Cited by
- 306
- References
- 33
- FWCI
- 25.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. https://app.cochat.ai/papers/10.1681/asn.2017070818
- The paper
- Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., Oberbauer, R., Posch, M., Staudenherz, A., Handisurya, A., Reeve, J., Halloran, P. F., & Böhmig, G. A. (2018). A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2017070818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.